ArticleBMJ case reports2016
Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema.
Article in BMJ case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Efficacy of topical carbonic anhydrase inhibitors in treating taxane drug-induced cystoid macular edema: A case report.Medicine · 2025Article
- Cystoid macular oedema without leakage in fluorescein angiography: a literature review.Eye (London, England) · 2023Review
- Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports.Journal of medical case reports · 2021Article
- Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review.Frontiers in oncology · 2021Article
- Unilateral cystoid macular edema and bilateral subfoveal hyperreflectivity following docetaxel chemotherapy: A case report.American journal of ophthalmology case reports · 2020Article
- Optical coherence tomography characteristics of taxane-induced macular edema and other multimodal imaging findings.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy.American journal of ophthalmology case reports · 2020Article
- Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.Clinical ophthalmology (Auckland, N.Z.) · 2019Review
- Unraveling the Mystery of Taxol-Induced Cystoid Macular Oedema: Case Report and Literature Review.Romanian journal of ophthalmologyReview
- Nab-Paclitaxel Induced Cystoid Macular Oedema: Case Report and Literature Review.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taxanes are a class of microtubule stabilising agents used to treat a wide range of malignancies. Taxane drug-induced cystoid macula oedema (TDICMO) is a known but rare complication of therapy. First reported with Docetaxel in 2003 and Paclitaxel in 2007, there are currently less than 20 cases of TDICMO in the literature. Although most cases resolve following taxane cessation, several authors have tried using carbonic anhydrase inhibitors or intravitreal bevacizumab to accelerate resolution or when taxane therapy cannot be discontinued. We report the first published case of TDICMO treated with a single-eye trial of topical dorzolamide versus intravitreal bevacizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.